ISO 12417-1:2024-02 (E)

Cardiovascular implants and extracorporeal systems - Vascular device-drug combination products - Part 1: General requirements

Contents

Page

Foreword v

Introduction vi

1 Scope 1

2 Normative references 2

3 Termsanddefinitions 2

4 Intended performance 6
4.1 General 6
4.2 Classification 6
4.3 Intended clinical location 7

5 Design attributes 7
5.1 General 7
5.2 Drug-containing part of the VDDCP 7
5.2.1 General 7
5.2.2 Matrix 8
5.2.3 Active pharmaceutical ingredient 8

6 Materials 9

7 Design evaluation 9
7.1 General 9
7.2 Pre-clinical evaluation 10
7.2.1 Sampling 10
7.2.2 Conditioning of test samples 10
7.2.3 Pre-clinical in vitro test reports and additional information 11
7.2.4 Pre-clinical in vitro evaluation 11
7.2.5 Preclinical in vivo evaluation 17
7.3 Clinical evaluation 22
7.3.1 Purpose 22
7.3.2 Specific aims 22
7.3.3 Clinical investigation plan 22
7.3.4 Data acquisition 23
7.3.5 Final report 25
7.4 Post-market surveillance 26

8 Manufacturing 26
8.1 General 26
8.2 Raw material reporting and analysis of the API 26
8.3 Raw material analysis and reporting for excipients 27
8.4 VDDCP batch release testing 27

9 Sterilization 28
9.1 Products supplied sterile -- Testing to support "Sterile" labelling 28
9.2 Products supplied non-sterile 28
9.3 Sterilization residuals 28

10 Packaging 28
10.1 General 28
10.2 Considerations for VDDCPs 28
10.3 Impact of changes in storage and shipping temperatures on VDDCP 28

11 Information supplied by the manufacturer 29
11.1 General 29
11.2 Labelling 29
11.2.1 VDDCP label(s) 29
11.2.2 Record label 29
11.3 Instructions for use 30

Annex A (informative) Description of potential clinical and technical events 31

Annex B (informative) Local information regarding submission issues for VDDCPs 36

Bibliography 42